Physician profile
Smita Gupta
NPI 1740284249
$13,196.68
in general payments reported to CMS, 2019-2025
45 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,987 · 2020: $3,429 · 2021: $4,178 · 2022: $1,933 · 2023: $229 · 2024: $250 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Long Term Medical Supply Or Device Loan: $19.98 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.60 |
| Long Term Medical Supply Or Device Loan | $19.98 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,994.22 | 2019-2022 | |
| Lilly USA, LLC | $1,243.08 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,096.03 | 2019-2022 | |
| Amgen INC. | $1,015.62 | 2019-2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $808.65 | 2019-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $795.60 | 2019-2022 | |
| Radius Health, INC. | $580.65 | 2019-2024 | Tymlos |
| Mannkind Corporation | $501.47 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $499.95 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $498.06 | 2019-2022 | |
| Amarin Pharma, INC. | $463.85 | 2019-2021 | |
| Corcept Therapeutics | $383.95 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $335.74 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.67 | 2019-2022 | |
| Ibsa Pharma INC. | $298.18 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.